Company intelligence / Profile preview

Jilin Sihuan Pharmaceutical

Ownership: Private
Development stage: Other

Overview

Jilin Sihuan Pharmaceutical is a major R&D and manufacturing hub within the Sihuan Pharmaceutical Holdings Group. It focuses on innovative drugs and generics across oncology, metabolic diseases (notably diabetes), cardiovascular/cerebrovascular conditions, and infectious diseases. The company has robust capabilities for both small molecules and biologics with several products at various clinical stages up to Phase 3. Its pipeline includes CDK4/6 inhibitors for cancer as well as insulin analogs and other agents for metabolic disorders.

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugate
Industry: Biotech

Drug pipeline

2 assets

Cattle Encephalon Glycoside and Ignotin

Unknown

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Jilin Sihuan Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jilin Sihuan Pharmaceutical.

Explore the full profile